Fulcrum Therapeutics Inc
NASDAQ:FULC

Watchlist Manager
Fulcrum Therapeutics Inc Logo
Fulcrum Therapeutics Inc
NASDAQ:FULC
Watchlist
Price: 3.25 USD 9.43% Market Closed
Market Cap: 202.8m USD
Have any thoughts about
Fulcrum Therapeutics Inc?
Write Note

Wall Street
Price Targets

FULC Price Targets Summary
Fulcrum Therapeutics Inc

Wall Street analysts forecast FULC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FULC is 5.39 USD with a low forecast of 2.02 USD and a high forecast of 14.7 USD.

Lowest
Price Target
2.02 USD
38% Downside
Average
Price Target
5.39 USD
66% Upside
Highest
Price Target
14.7 USD
352% Upside

FULC Last Price Targets
Fulcrum Therapeutics Inc

The latest public price target was made on Sep 13, 2024 by Andrew Fein from H.C. Wainwright , who expects FULC stock to rise by 23% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Andrew Fein
H.C. Wainwright
4 USD
Upside 23%
2 months ago
Sep 13, 2024
Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TheFly
Gregory Renza
RBC Capital
4 USD
Upside 23%
2 months ago
Sep 12, 2024
Fulcrum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
TheFly
Tazeen Ahmad
Bank of America Securities
2 USD
Downside 38%
2 months ago
Sep 12, 2024
BofA Securities Downgrades Fulcrum Therapeutics (FULC) to Underperform
StreetInsider
Dae Gon Ha downgraded Fulcrum Therapeutics
Stifel Nicolaus
3 USD
Downside 8%
2 months ago
Sep 12, 2024
Fulcrum Therapeutics downgraded to Hold from Buy at Stifel
TheFly
Tazeen Ahmad
Bank of America Securities
10 USD
Upside 208%
2 months ago
Sep 9, 2024
BofA Securities Upgrades Fulcrum Therapeutics (FULC) to Neutral
StreetInsider
Gregory Renza
RBC Capital
15 USD
Upside 362%
2 months ago
Sep 3, 2024
Fulcrum Therapeutics (FULC) PT Raised to $15 at RBC Capital
StreetInsider
Kristen Kluska
Cantor Fitzgerald
23 USD
Upside 608%
6 months ago
May 20, 2024
Cantor Fitzgerald Starts Fulcrum Therapeutics (FULC) at Overweight
StreetInsider
Dae Gon Ha
Stifel Nicolaus
22 USD
Upside 577%
6 months ago
May 13, 2024
Fulcrum Therapeutics (FULC) PT Raised to $22 at Stifel
StreetInsider
Corinne Jenkins
Goldman Sachs
15 USD
Upside 362%
6 months ago
May 13, 2024
Goldman Sachs Upgrades Fulcrum Therapeutics (FULC) to Buy
StreetInsider
Gregory Renza
RBC Capital
14 USD
Upside 331%
8 months ago
Mar 13, 2024
RBC Capital Starts Fulcrum Therapeutics (FULC) at Outperform, 'A Rare Disease Pipeline with Its DUX in a Row'
StreetInsider
Show More Price Targets
Show Less Price Targets
Andrew Fein
H.C. Wainwright
Price Target 4 USD
Upside/Downside 23%
View Source
Gregory Renza
RBC Capital
Price Target 4 USD
Upside/Downside 23%
View Source
Tazeen Ahmad
Bank of America Securities
Price Target 2 USD
Upside/Downside 38%
View Source
Dae Gon Ha downgraded Fulcrum Therapeutics
Stifel Nicolaus
Price Target 3 USD
Upside/Downside 8%
View Source
Tazeen Ahmad
Bank of America Securities
Price Target 10 USD
Upside/Downside 208%
View Source
Gregory Renza
RBC Capital
Price Target 15 USD
Upside/Downside 362%
View Source
Kristen Kluska
Cantor Fitzgerald
Price Target 23 USD
Upside/Downside 608%
View Source
Dae Gon Ha
Stifel Nicolaus
Price Target 22 USD
Upside/Downside 577%
View Source
Corinne Jenkins
Goldman Sachs
Price Target 15 USD
Upside/Downside 362%
View Source
Gregory Renza
RBC Capital
Price Target 14 USD
Upside/Downside 331%
View Source
Show More Price Targets
Show Less Price Targets
Fulcrum Therapeutics Inc Competitors:
Price Targets
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
26% Upside
AVDL
Avadel Pharmaceuticals PLC
106% Upside
PHAT
Phathom Pharmaceuticals Inc
176% Upside
BSEM
Biostem Technologies Inc
138% Upside
MRK
Merck & Co Inc
35% Upside
000739
Apeloa Pharmaceutical Co Ltd
30% Upside

Revenue
Forecast

Revenue Estimate
Fulcrum Therapeutics Inc

The compound annual growth rate of Fulcrum Therapeutics Inc's revenue for the next 3 years is 171%.

N/A
Past Growth
171%
Estimated Growth
Estimates Accuracy
25%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Fulcrum Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Fulcrum Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-41%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FULC's stock price target?
Price Target
5.39 USD

According to Wall Street analysts, the average 1-year price target for FULC is 5.39 USD with a low forecast of 2.02 USD and a high forecast of 14.7 USD.

What is Fulcrum Therapeutics Inc's Revenue forecast?
Projected CAGR
171%

The compound annual growth rate of Fulcrum Therapeutics Inc's revenue for the next 3 years is 171%.

Back to Top